BiotechTube

Mesalazine

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colitis, Ulcerative

Conditions

Colitis, Ulcerative

Trial Timeline

Mar 1, 2024 → Aug 1, 2025

NCT ID
NCT06176560

About Mesalazine

Mesalazine is a phase 3 stage product being developed by Faes Farma for Colitis, Ulcerative. The current trial status is unknown. This product is registered under clinical trial identifier NCT06176560. Target conditions include Colitis, Ulcerative.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06176560Phase 3UNKNOWN

Competing Products

20 competing products in Colitis, Ulcerative

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
GSK3050002 + PlaceboEisaiPhase 1
33
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52

Other Products from Faes Farma

Bilastine + Desloratadine + PlaceboPhase 3
72
Hemorrane plus + Hemorrane + PlaceboPhase 3
72
Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic Solution 0.025% (Zaditen) + Vehicle of Bilastine Ophthalmic SolutionPhase 3
72
Bilastine + PlaceboPhase 3
72
bilastine + Cetirizine + PlaceboPhase 3
72